免疫治療薬の世界市場

【英語タイトル】Immunotherapy Drugs: Global Markets

BCC Researchが出版した調査資料(BCC21AP012)・商品コード:BCC21AP012
・発行会社(調査会社):BCC Research
・発行日:2021年3月
・ページ数:143
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,500 ⇒換算¥814,000見積依頼/購入/質問フォーム
Multi UserUSD6,600 ⇒換算¥976,800見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

本調査レポートでは、免疫治療薬の世界市場を調査・分析し、イントロダクション、サマリー・ハイライト、市場/技術背景、市場動向、新型コロナウイルス感染症の影響、製品別(モノクローナル抗体、チェックポイント阻害薬、ペンブロリズマブ、コンパニオン診断、臨床試験プログラム、その他)分析、地域別分析、企業情報などを掲載しています。
・イントロダクション
・サマリー・ハイライト
・市場/技術背景
・市場動向
・新型コロナウイルス感染症の影響
・免疫治療薬の世界市場規模:製品別(モノクローナル抗体、チェックポイント阻害薬、ペンブロリズマブ、コンパニオン診断、臨床試験プログラム、その他)
・免疫治療薬の世界市場規模:地域別
・企業情報

The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins. This report does not include other immunotherapies such as vaccines and hormones.

The scope of the report includes an overview of the global market and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.

The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers and regional dynamics of the global market and current trends within the industry.

Regional analysis includes North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan and Rest of Asia-Pacific) and rest of the world (RoW).

Report Includes:
- 20 data tables and 26 additional tables
- An overview of the global market for immunotherapy drugs
- Estimation of the market size and analyses of global market trends, with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) though 2025
- Evaluation of current market size and forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
- Description of immunotherapy, combination immunotherapy and discussion on how it targets on cell-mediated adaptive immunity
- Market share analysis of the immunotherapy drugs based on type of drug, therapy area, end user and region
- Information on personalized treatment paradigm, details of clinically significant types of cancers and discussion on future of immunotherapy in cancer
- Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and novel targeted approaches for immunotherapy
- Discussion on fine tuning versus boosting cancer immunity and early versus advanced stage cancer immunotherapy
- Market share analysis of the major players in the industry, and discussion on their technological strengths and weakness, and innovative marketing practices
- Comprehensive company profiles of major players of the industry, including Amgen Inc., Bayer AG, Johnson & Johnson, Novartis AG and Pfizer Inc.

Summary:
By product type, the immunotherapy drugs market is divided into the following segments -
- Monoclonal antibodies.
- Checkpoint inhibitors.
- Interferons and interleukins.

In 2019, the global market for immunotherapy drugs was REDACTED and is expected to reach REDACTED with a CAGR of REDACTED by the forecast year 2025.

The monoclonal antibodies segment accounted for the largest share of the global market for immunotherapy drugs in 2019.This large share can be attributed to several factors including their high specificity and fewer side-effects; the increasing focus on personalized medicines; initiatives by industry players; and the growing target disease incidence and patient pool.

In 2019, the market for monoclonal antibodies was $106.8 billion and estimated to reach REDACTED by 2025 with a CAGR of REDACTED.

$ 5500 – 1 User License – PDF
Get Report
Pay by invoiceGet a quote
Ahmad helps you find the right report:
+1 718 618 4302
Contact by email
FAQ
Delivery time
User license
Payment options
Testimonials
The market research advisor answered my questions quickly and professionally. ReportBuyer’s team did their best to ensure that I felt comfortable before making the investment to purchase the report.
Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

❖ レポートの目次 ❖

Chapter 1 Introduction
Study Goals and Objectives
Scope of Report
Methodology
Market Estimates
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Analyst’s Credentials

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background
Immunotherapy
Towards Combination Immunotherapy
Focusing on Cell-mediated Adaptive Immunity
Fine Tuning Vs. Boosting Cancer Immunity
Early Vs. Advanced Stage Cancer Immunotherapy
Personalized Treatment Paradigm
Clinically Significant Types of Cancers
Lung Cancer
Breast Cancer
Colorectal Cancer
Stomach Cancer
Leukemia
Future of Immunotherapy in Cancer
Infectious Diseases
Immunotherapy against Autoimmune Disorders
Immunotherapies against Infectious Diseases
Biologics as Autoimmune Disorder Therapies
Trends in Autoimmune Disorder Therapies
Types of Immunotherapies
Checkpoint Inhibitors
Unmet Medical Needs
New Biomarkers to Stratify Patients
Relapse/Refractory Patients
Treatment Efficacy and Tolerability
Innovative Strategies
Novel Targeted Approaches
Monoclonal Antibodies
Interleukins
Interferons

Chapter 4 Market Dynamics
Strengths of Immunotherapy Market
Growing Aging Population
Rising Incidence of Diseases
Patent Expirations
Growing Pipeline
Drive to Reduce Costs
Government Incentives
Collaborations and Partnerships
Mergers and Acquisitions
Weaknesses of the Immunotherapy Market
Manufacturing Process
Process Definition and Testing and Validation
Lack of Skilled Personnel
Regulatory Guidelines
Patent Litigation
Threats to Immunotherapy Market
Unpredictable Regulatory Landscape
Prescriptions by Medical Practitioners/Pharmacies
Competition
Opportunities in the Immunotherapy Market
Emerging Markets
Technological Innovation and Improved Process Knowledge
Pricing

Chapter 5 Impact of COVID-19 on the Pharmaceutical Industry
Short-term Impact
Change in Demand
Shift of Communication and Promotions to Remote Interactions
Changes to R&D
Long-term Impact
Delayed Approvals for Non-COVID-related Pharmaceutical Products
Self-sufficiency in the Pharmaceutical Industry
Changes in Consumption Trends in Health-related Products

Chapter 6 Market Breakdown by Product Type
Overview
Monoclonal Antibodies
Market Overview
Market Revenue
Market Share
Market by Region
Market Overview
Market Revenue
Market Share
Checkpoint Inhibitors
Pembrolizumab
Companion Diagnostic
Clinical Trial Program
Forecast for Pembrolizumab
Nivolumab (Opdivo)
Companion Diagnostic
Clinical Trial Program
Forecast for Nivolumab
Atezolizumab (Tecentriq)
Companion Diagnostic
Clinical Trial Program
Forecast for Atezolizumab
Avelumab (Bavencio)
Companion Diagnostic
Clinical Trial Program
Forecast for Avelumab
Durvalumab (Imfinzi)
Companion Diagnostic
Clinical Trial Program
Durvalumab Forecasts
Yervoy (Ipilimumab)
Market by Region
Market Revenue
Market Share
Interferons and Interleukins
Market Revenue
Market by Region
Market by Disease Area

Chapter 7 Market Breakdown by Region
Market Overview and Discussion
North America
United States
Canada
Europe
Asia-Pacific
China
Japan
Rest of the World

Chapter 8 Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL MYERS SQUIBB
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON
VIATRIS INC. (FORMERLY MYLAN)
NOVARTIS AG
PFIZER INC.
VERTEX PHARMACEUTICALS INC.



★調査レポート[免疫治療薬の世界市場] (コード:BCC21AP012)販売に関する免責事項を必ずご確認ください。
★調査レポート[免疫治療薬の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆